A review on the immune responses against novel emerging coronavirus (SARS-CoV-2)

R Lotfi, RN Kalmarzi, SA Roghani - Immunologic research, 2021 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by a
newly identified coronavirus called the severe acute respiratory syndrome-coronavirus 2 …

Perspectives on targeting IL-6 as a potential therapeutic strategy for COVID-19

Y Khaedir, R Kartika - Journal of Interferon & Cytokine Research, 2021 - liebertpub.com
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and has been a major threat to global public health. In …

Cellular immune response to COVID-19 and potential immune modulators

X Zhou, Q Ye - Frontiers in Immunology, 2021 - frontiersin.org
Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Droplets and contacts serve as …

Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation

I Amigues, AH Pearlman, A Patel, P Reid… - Expert review of …, 2020 - Taylor & Francis
Introduction: The mortality of coronavirus disease 2019 (COVID-19) is frequently driven by
an injurious immune response characterized by the development of acute respiratory …

[HTML][HTML] Cytokine storm in novel coronavirus disease (COVID-19): expert management considerations

Y Mehta, SB Dixit, KG Zirpe… - Indian journal of critical …, 2020 - ncbi.nlm.nih.gov
Background Cytokine storm is caused by the colossal release of proinflammatory cytokines
[eg, IL (interleukin)-2, IL-6, IL-8 TNF (tumor necrosis factor)-α, etc.] causing dysregulated …

The immune system and COVID-19: Friend or foe?

F Yazdanpanah, MR Hamblin, N Rezaei - Life sciences, 2020 - Elsevier
Abstract Aim Coronavirus disease 2019 (COVID-19) is a novel highly contagious infection
caused by SARS-CoV-2, which has been became a global public health challenge. The …

Immunomodulatory drugs in the management of SARS-CoV-2

DR Burrage, S Koushesh, N Sofat - Frontiers in immunology, 2020 - frontiersin.org
With the onset of the global pandemic in 2020 of Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain …

Immune Profiling of COVID-19 in Correlation with SARS and MERS

BA Khalil, SB Shakartalla, S Goel, B Madkhana… - Viruses, 2022 - mdpi.com
Acute respiratory distress syndrome (ARDS) is a major complication of the respiratory illness
coronavirus disease 2019, with a death rate reaching up to 40%. The main underlying cause …

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

M Catanzaro, F Fagiani, M Racchi, E Corsini… - Signal transduction and …, 2020 - nature.com
To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19
and the current standard care relies on supportive treatments. Therefore, based on the fast …

Novel coronavirus disease 2019 (COVID-19) and cytokine storms for more effective treatments from an inflammatory pathophysiology

S Yokota, T Miyamae, Y Kuroiwa… - Journal of Clinical …, 2021 - mdpi.com
The Novel Coronavirus Disease 2019 (COVID-19) has swept the world and caused a global
pandemic. SARS-CoV-2 seems to have originated from bats as their reservoir hosts over …